IMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose and treat disease, has successfully brought its Series A to over £40 million.

The oversubscribed financing round was co-led by IQ Capital and Molten Ventures, and supported by The British Business Bank and Meltwind alongside existing investors.

IMU has built the world’s largest immune dataset, scaling to more than 25,000 individuals in 2026 through unrivalled access to patient samples and population wide clinical data. By combining high-fidelity multi-omic analysis with proprietary machine learning analytics, IMU can use a simple blood sample to measure over 100 million immune data points, creating the most detailed immune picture ever assembled at clinical scale.

With its data, the company is establishing a universal standard for immune profiling which will enable the discovery of new immune mechanisms and identify precision approaches, monitor disease progression and the course of treatment, and predict treatment suitability and efficacy for individual patients.

The funding will also be used to advance IMU’s clinical programmes including its Stem Cell Transplant and Solid Organ Transplant Programmes in addition to MANIFEST, a ground- breaking UK research consortium investigating patient response to cancer immunotherapies.